The Roxbury Institute Appoints Dr. Karen Herbst to Lead Lipedema Research

The Roxbury Institute, known for its pioneering work in lipedema treatment, has appointed Dr. Karen Herbst as Head of Research and Director of Diagnostic and Preventative Medicine. This strategic partnership aligns with the institute's mission to improve understanding and treatment of lipedema, a chronic disease affecting millions of women globally.

Dr. Herbst, a board-certified endocrinologist with over two decades of experience, is celebrated for her significant contributions to lipedema research. She has led efforts to better characterize the disease, which is often misdiagnosed as obesity. Her work includes a focus on lymphatic and vascular comorbidities, metabolic and hormonal factors, and inflammatory implications.

In her new role, Dr. Herbst aims to integrate advanced research with innovative diagnostic and preventative therapies, setting new standards of care for lipedema. Dr. David Amron, The Roxbury Institute's founder, expressed enthusiasm about the collaboration, citing Dr. Herbst's expertise as crucial for advancing treatment options beyond surgery.

Dr. Herbst's achievements include leading a 2019 NIH-sponsored conference to establish the first Standard of Care Guidelines for Lipedema in the U.S. and introducing new ICD-10 codes for lipedema and Dercum's disease at the CDC. She will also maintain an active clinical practice, offering personalized care to patients.